Site icon pharmaceutical daily

Outlook on the Cystic Fibrosis Therapeutics Global Market to 2025 – by Drug Class, Drug Molecule Type, Route of Administration, End-user and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering.

The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Looking forward, the publisher expects the market to continue to exhibit strong growth during 2020-2025.

Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.

The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body.

Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further.

Key Questions Answered in this Report:

(Read more…)

Key Topics Covered:

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Forecast

6 Market Breakup by Drug Class

6.1 Pancreatic Enzyme Supplements

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Mucolytics

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 Bronchodilators

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 CFTR Modulators

6.4.1 Market Trends

6.4.2 Market Forecast

6.5 Antibiotics

6.5.1 Market Trends

6.5.2 Market Forecast

6.6 Others

6.6.1 Market Trends

6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

7.1 Small Molecule Drugs

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Biologics

7.2.1 Market Trends

7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral Drugs

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Inhaled Drugs

8.2.1 Market Trends

8.2.2 Market Forecast

9 Market Breakup by End-User

9.1 Hospitals

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Clinics

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 Others

9.3.1 Market Trends

9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America

10.2 Asia Pacific

10.3 Europe

10.4 Latin America

10.5 Middle East and Africa

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Indicators

15 Competitive Landscape

15.1 Market Structure

15.2 Key Players

15.3 Profiles of Key Players

15.3.1 Abbvie Inc.

15.3.2 Alaxia

15.3.3 Alcresta Therapeutics Inc.

15.3.4 Allergan

15.3.5 AstraZeneca

15.3.6 F. Hoffmann-La Roche Ltd

15.3.7 Gilead Sciences Inc.

15.3.8 Merck & Co., Inc.

15.3.9 Novartis AG

15.3.10 Teva Pharmaceutical Industries Ltd.

15.3.11 Vertex Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/zabl3a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version